Reviewed by MedNext Clinical Team
Furosemide is the most widely used loop diuretic and a cornerstone of treatment for fluid overload in heart failure, hepatic cirrhosis, nephrotic syndrome, and chronic renal impairment. Despite its widespread use, furosemide carries significant risks — particularly electrolyte disturbances and, at high intravenous doses, ototoxicity — that require careful monitoring in clinical practice [1].
Mechanism of Action
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This generates a powerful diuresis — far more potent than thiazide diuretics — and is effective even when GFR is substantially reduced. Furosemide also has vasodilatory effects on the venous capacitance vessels, providing rapid symptomatic relief in acute pulmonary oedema before diuresis is established [1].
Heart Failure Management
In chronic heart failure, furosemide is titrated to achieve and maintain euvolaemia. Typical starting doses range from 20–40 mg once or twice daily, with higher doses required as renal function declines or tolerance develops. In decompensated heart failure, intravenous furosemide provides more reliable and rapid diuresis than oral dosing — the equivalent IV dose is typically half the oral dose due to reduced oral bioavailability in fluid-overloaded states.
Flexible ("sliding scale") dosing strategies, where patients adjust their own furosemide dose based on daily weight and symptoms, improve outcomes and reduce hospitalisation in selected, well-educated patients.
Electrolyte Monitoring
Furosemide causes renal losses of potassium, sodium, magnesium, and to a lesser extent calcium. The following should be monitored regularly:
- Potassium (K+): Hypokalaemia is the most common electrolyte disturbance. Serum K+ below 3.5 mmol/L increases the risk of cardiac arrhythmias, particularly in patients on digoxin. Potassium supplementation or co-prescribing a potassium-sparing diuretic (spironolactone, amiloride) is often required.
- Sodium (Na+): Hyponatraemia may develop, particularly in elderly patients or those with high fluid intake. Restricting free water intake is often necessary.
- Magnesium (Mg2+): Hypomagnesaemia is underrecognised and may contribute to refractory hypokalaemia — correcting magnesium is essential when both deficiencies coexist.
- Renal function: Check urea, creatinine, and electrolytes at baseline and regularly during treatment, especially during dose changes [1].
Ototoxicity
High-dose intravenous furosemide can cause sensorineural hearing loss, tinnitus, and vertigo — effects that may be transient or, in severe cases, permanent. Ototoxicity is related to peak plasma concentration and is most likely when furosemide is given as a rapid intravenous bolus at high doses, particularly in patients with renal impairment (which further elevates furosemide levels). To minimise this risk, intravenous furosemide should not be infused faster than 4 mg/min, and the maximum single IV dose should not exceed 250 mg in most patients. Concomitant use of other ototoxic drugs (e.g., aminoglycosides, cisplatin) further increases the risk.
Renal Function and Dose Adjustment
Furosemide retains efficacy in moderate-to-severe renal impairment, but higher doses are needed to achieve adequate tubular concentrations. Unlike many drugs, furosemide does not require dose reduction in renal impairment — rather, doses may need to be increased to maintain diuretic effect. A significant rise in creatinine during treatment warrants reassessment of volume status and possible dose reduction if the patient is volume-depleted rather than fluid-overloaded.
References
- Brater DC. Diuretic therapy. NEJM. 1998;339:387-395.